Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | PDE2A | O00408 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3120308 | 0.78 | CTSL (0.43) | CTSLCTSK | |
| SCHEMBL3120324 | 0.77 | NPC1 (0.36) | CTSLCTSKALDH1A1 | |
| SCHEMBL2540747 | 0.77 | CYP1A2 (0.35) | — | |
| SCHEMBL19253740 | 0.74 | CTSL (0.37) | CTSLCTSKHTT | |
| SCHEMBL27659663 | 0.73 | GABRA1 (0.33) | PDE2AHTTALDH1A1 | |
| SCHEMBL19253667 | 0.73 | HPGD (0.35) | CTSLCTSKHPGDHTTPOLB | |
| SCHEMBL19253599 | 0.73 | HPGD (0.35) | CTSLCTSKHPGDHTTPOLB | |
| SCHEMBL14994640 | 0.73 | PDE4B (0.35) | — | |
| SCHEMBL4481632 | 0.72 | CNR1 (0.36) | — | |
| SCHEMBL30623726 | 0.71 | MAPT (0.40) | HPGDHTTPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10072025-B2 | Ethyl N-boc piperidinyl pyrazolo pyridones as Janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-09-11 | — | — | US | disclosed |
| US-20170240567-A1 | ETHYL N-BOC PIPERIDINYL PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170240567-A1 | ETHYL N-BOC PIPERIDINYL PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | JAK1, JAK2, JAK3 | CTSL 1574/4885CTSK 668/4885PDE2A 466/4885 |
| US-10072025-B2 | Ethyl N-boc piperidinyl pyrazolo pyridones as Janus kinase inhibitors | JAK1, JAK2, JAK3 | CTSL 1574/4885CTSK 668/4885PDE2A 466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.